Unlimited Sciences, a psychedelic research nonprofit, will be carrying out an observational research study that will measure the potential healing effects of Ayahuasca on individuals with...
A new study conducted by Columbia University Mailman School of Public Health and Columbia University Irving Medical Center estimates that over 5.5 million people in the US used hallucinogens...
Cybin Inc.
Small Pharma has received approval for an interaction study between the company’s lead N, N-dimethyltryptamine (DMT) candidate – SPL026 – and serotonin reuptake inhibitors (SSRIs).
Launched by Subreddit r/HPPD in partnership with the scientific research app Quantified Citizen, the retrospective, observational study aims to investigate possible links between Hallucinogen Persisting Perception...
The medical use of ketamine to alleviate symptoms of depression carries a low risk of addiction, suggests new research from the University of Geneva (UNIGE).
Biopharmaceutical company Silo Pharma has carried out an animal study investigating the topical administration of ketamine for pain reduction.
COMPASS Pathways has launched its multi-centre, doubleblind randomised controlled Phase 2 clinical trial investigating the efficacy of its proprietary formulation of synthetic psilocybin, COMP360, in people...
Psyched Wellness has announced preliminary data from tests completed by the National Research Council of Canada (NRC) on its extract AME-1.
The UNC School of Medicine has found that variants in one serotonin receptor in neurons could be why some patients fare much better after psychedelic therapy...